The Role of Chromosomal Translocations in Hematologic Malignancies: Mechanistic Insights and Clinical Correlates
Year: 2026
Type: article
Abstract: Chromosomal translocations are central drivers of hematologic malignancies, reshaping gene regulation, altering epigenetic states, and generating oncogenic fusion proteins that initiate and sustain malignant transformation. Advances in whole-genome sequencing, long-read mapping, and single-cell multiomics have expanded the catalog of recurrent and cryptic rearrangements while illuminating mechanisms such as enhancer hijacking, 3D chromatin architecture disruption, aberrant V(D)J recombination, and defective DNA repair. These insights reveal how translocations activate lineage-specific oncogenic programs across leukemias, lymphomas, and plasma-cell neoplasms. Clinically, translocations refine diagnostic classification, guide prognostic stratification, and increasingly direct targeted therapy, with fusion-specific agents, epigenetic modulators, and kinase inhibitors transforming outcomes for select subtypes. Their role in measurable residual disease (MRD) monitoring further enhances treatment precision. This review synthesizes recent mechanistic and clinical advances, emphasizing how an improved understanding of translocation biology is reshaping precision medicine in hematologic oncology. Peer Review History: Received 5 June 2026; Reviewed 9 July 2026; Accepted 6 August; Available online 15 September 2026 Academic Editor: Dr. Ahmad Najib, Universitas Muslim Indonesia, Indonesia, [email protected] Reviewers: Dr. Jucimary Vieira dos Santos, Hemonorte Dalton Barbosa Cunha, Brazil, [email protected] Dr. George Zhu, Tehran University of Medical Sciences, Tehran, Iran, [email protected]
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: chromosomal translocation, hematologic malignancies, fusion protein, enhancer hijacking, 3D genome organization, V(D)J recombination, DNA repair deficiency, leukemia, lymphoma, plasma cell neoplasms, minimal residual disease, targeted therapy, epigenetic regulators, kinase inhibitors, precision medicine
Open Access status: diamond
OpenAlex ID: W7213398561
